The Longevity Reality Radar
46 approaches, rated by evidence.

Creatine and cancer immunotherapy

Creatine to potentiate immunotherapy. Cancer. Reviewed Jul 2026.

Improved anti-tumour immune signalling in mouse melanoma and has not been tested in people with cancer.

Stage
Preclinical
Rung: Experimental. Animal, lab or theoretical. Years away, if ever.
Evidence grade
D
mouse study
Animal or lab only, single pilot, or case reports. How grades work.

What it is

The cheap, common gym supplement repurposed to energize the immune cells that detect tumors and activate killer T-cells.

The evidence

UCLA (2026): creatine boosted dendritic-cell activation and improved anti-tumor immune signaling in mouse melanoma models. Human cancer trials not yet done.

What you can do today

Not available for this use, and years away if it arrives at all. Anything sold today with this claim is not backed by human evidence for it.

Sources

  • Coverage, not a sourcex.com

No primary paper or registry record is linked for this entry yet. The evidence summary names the studies it relies on.

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Cancer

All 9 in Cancer.

  • Pelareorep for pancreatic cancerGrade C, response rates only. Phase 3, pancreatic cancer.Response rates in later-line settings beat the approved comparator, but that is not randomised survival data and the Phase 3 has not reported.
  • mRNA-4157 melanoma vaccineGrade B, Phase 3 unpublished. Phase 3, positive topline.Phase 3 beat Keytruda alone on recurrence, but only a press release exists, hazard ratios are unpublished and overall survival is immature.
  • mRNA vaccine for pancreatic cancerGrade C, small early trial. Phase 1/2, pancreatic cancer.Nearly 90% of patients whose immune system responded were alive up to six years later in a small early trial, and randomised survival results have not been reported.
  • CAR-T for solid tumoursGrade C, early responses. Phase 1/2.Encouraging early responses in gastric and some childhood tumours, but it is not curative for most solid cancers.
  • CRISPR-Cas12a2 for p53 cancersGrade D, lab only. Preclinical, lab only.Selectively killed p53-mutant cells in the lab, and nobody yet knows how to deliver it to every tumour cell in a living body.
  • Ivermectin for cancerGrade D, case reports. Preclinical, case reports.Lab and mouse data plus uncontrolled case reports, no controlled human trial, and self-treating melanoma risks a fatal delay.